Thursday, February 19, 2026 2/19/2026

Processes mediated by polypeptides

Award Number: R35GM151985
ORGANIZATION: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 02/01/2024
PERIOD OF PERFORMANCE END DATE: 01/31/2029

Group Awards By:

View Award Description

Processes mediated by polypeptides - SUMMARY The proposed research focuses on processes that are mediated by proteins, that are crucial for cellular physiology and that are dysregulated in human disease. This effort has two components that differ topically but share common themes in experimental design. Fundamental mechanistic insight is our primary goal, but outcomes could support future therapeutic advances. We use chemically synthesized polypeptides to test molecular hypotheses, an approach that transcends the compositional limitations of biosynthetic polypeptides. One major focus involves signal transduction by a set of G protein-coupled receptors (GPCRs) that are naturally modulated by long polypeptide hormones (B family GPCRs). Agents that activate these receptors are used in human medicine. We conduct parallel studies with multiple receptors so that we can discern which features of the signal transduction process are conserved and which features are unique to specific receptors. We have previously explored the parathyroid hormone receptor-1 (PTHR1) and the glucagon-like peptide-1 receptor (GLP-1R), agonists of which are used to treat osteoporosis or type 2 diabetes, respectively. Continuing work on these two receptors will be complemented by new studies with the glucagon receptor (GCGR; glucagon is used by diabetes patients to reverse hypoglycemic shock) and the GLP-2 receptor (GLP-2R; agonists are used to treat short-bowel syndrome). Proposed studies will harness unique capabilities of our group to explore the consequences of varying agonist conformational propensities in terms of signaling outcomes and receptor binding. Results should be very impactful because agonist design efforts motivated by therapeutic goals usually focus on stabilizing a specific receptor-bound conformation of the agonist, which is fully α-helical for the GPCR agonists we study. Our recent findings raise questions about this approach; we have discovered surprisingly potent agonists based on designs that destabilize the α-helical conformation. The other major research focus is liquid-liquid phase separation (LLPS) mediated by proteins. LLPS in cells leads to a variety of “membraneless organelles” (MOs) that appear to be crucial for cellular function. The noncovalent interactions that underlie these dynamic assemblies are not well understood. Evolution of dynamic MOs toward more ordered assemblies appears to underlie some neurodegenerative diseases. Our approach involves developing models of protein-mediated LLPS in which one component is a peptide of < 50 residues and therefore readily accessible via chemical synthesis; the other component is a larger biopolymer (protein or RNA). This design strategy enables incisive evaluation of the roles of diverse noncovalent interactions in the dynamic associations that are unique to MOs. Results should inform future efforts to address diseases associated with “hardening” of MOs within cells.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $578,813 )
2026	2026	UNIVERSITY OF WISCONSIN SYSTEM	21 N PARK ST STE 6301	MADISON	WI	53715	DANE	USA	Biomedical Research and Research Training	000	3	1/15/2026	NON-COMPETING CONTINUATION	$578,813
														Subtotal = $578,813

Issue Date FY: 2025 ( Subtotal = $643,125 )
2025	2025	UNIVERSITY OF WISCONSIN SYSTEM	21 N PARK ST STE 6301	MADISON	WI	53715	DANE	USA	Biomedical Research and Research Training	001	2	1/27/2025	NON-COMPETING CONTINUATION	$578,813
2025	2025	UNIVERSITY OF WISCONSIN SYSTEM	21 N PARK ST STE 6301	MADISON	WI	53715	DANE	USA	Biomedical Research and Research Training	002	2	8/13/2025	NON-COMPETING CONTINUATION	$64,312
2025	2025	UNIVERSITY OF WISCONSIN SYSTEM	21 N PARK ST STE 6301	MADISON	WI	53715	DANE	USA	Biomedical Research and Research Training	003	2	8/15/2025	NON-COMPETING CONTINUATION	$0
2025	2024	UNIVERSITY OF WISCONSIN SYSTEM	21 N PARK ST STE 6301	MADISON	WI	53715	DANE	USA	Biomedical Research and Research Training	000	1	11/25/2024	NEW	$0
														Subtotal = $643,125

Issue Date FY: 2024 ( Subtotal = $519,921 )
2024	2024	UNIVERSITY OF WISCONSIN SYSTEM	21 N PARK ST STE 6301	MADISON	WI	53715	DANE	USA	Biomedical Research and Research Training	000	1	1/23/2024	NEW	$519,921
														Subtotal = $519,921

Grand Total All Awards = $1,741,859

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Processes mediated by polypeptides

Award Number: R35GM151985

ORGANIZATION: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 02/01/2024

PERIOD OF PERFORMANCE END DATE: 01/31/2029

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer